Jasper Therapeutics(US:JSPR) Globenewswire·2025-09-30 14:40Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Jasper Therapeutics, Inc. due to alleged violations of federal securities laws, with a deadline for investors to seek lead plaintiff status in a class action lawsuit by November 18, 2025 [3][5]. Group 1: Allegations Against Jasper - The complaint alleges that Jasper and its executives made false and misleading statements regarding the company's manufacturing controls and compliance with cGMP regulations, which could negatively impact clinical trial results and the commercial prospects of its products, particularly briquilimab [5]. - It is claimed that Jasper's failure to ensure proper manufacturing processes increased the likelihood of cost-reduction measures and overstated the company's business and financial prospects [5]. Group 2: Recent Developments - On July 7, 2025, Jasper reported issues with a drug product lot used in clinical trials, leading to a significant drop in stock price by $3.73 per share, or 55.1%, closing at $3.04 per share [6]. - The company announced a halt in the ETESIAN Study and paused development in asthma and SCID, contradicting previous statements about having a strong financial position [6]. Group 3: Legal Proceedings - Investors who suffered losses in Jasper between November 30, 2023, and July 3, 2025, are encouraged to contact Faruqi & Faruqi to discuss their legal options [1]. - The firm is also seeking information from whistleblowers, former employees, and shareholders regarding Jasper's conduct [8].